What It Is
Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), often described as GRF 1-29 because it reproduces the biologically active first 29 amino acids of the full-length hormone.[1] It belongs to a drug class called growth hormone secretagogues: compounds that prompt the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly the way recombinant somatropin (HGH) does.
Sermorelin has a notable regulatory history. It was previously marketed in the United States as an FDA-approved prescription drug (brand name Geref) for evaluating and treating pediatric growth hormone deficiency, but that approved product was later discontinued and is no longer commercially available. Today, sermorelin circulates mainly as a compounded or research-labeled peptide sold outside the FDA-approved drug pathway, which is a meaningfully different regulatory situation than an active, approved medication.
How It Works
Sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular signaling that leads to pulsatile growth hormone release.[2] Growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1 (IGF-1), which is commonly used as a downstream marker of growth hormone activity.
Because this pathway depends on a functioning pituitary gland, sermorelin's effects are self-limited by the body's own feedback loops involving somatostatin and IGF-1 — it cannot force growth hormone release beyond what the pituitary is physiologically capable of producing. This upstream mechanism is the key distinction from direct HGH replacement, and it also means sermorelin may do little for people whose pituitary somatotroph reserve is severely damaged.
What the Research Shows
The strongest evidence for sermorelin comes from its historical, labeled use in pediatric growth hormone deficiency, where it was studied for stimulating or diagnosing deficient growth hormone secretion in children under specialist endocrine care.[3] Guidelines from pediatric endocrine societies continue to frame growth hormone axis treatment as a diagnosis-driven, specialist-managed decision, not a general wellness intervention.
Evidence is much weaker for the anti-aging, sleep, and body-composition claims that dominate online marketing. A systematic review of growth hormone therapy in healthy older adults found only small body-composition changes alongside increased adverse events, and did not establish any anti-aging benefit.[4] Because sermorelin acts on the same growth hormone axis, that same caution applies: a plausible mechanism does not equal a proven benefit in otherwise healthy adults.
Safety & Side Effects
Historical labeling for sermorelin listed injection-site reactions, flushing, headache, nausea, dizziness, somnolence, and hypersensitivity-type reactions as reported side effects.[3] Because it stimulates the growth hormone axis, clinicians also weigh theoretical GH-related risks such as fluid retention, joint symptoms, and glucose changes, particularly in people with diabetes, active cancer, sleep apnea, or pituitary disease.
An important caveat: this safety data comes from a formally reviewed, discontinued drug label. Compounded or research-sold sermorelin products are not evaluated by the FDA for purity, potency, or manufacturing quality, so their real-world safety profile may differ from what the historical label describes.[5]
Regulatory Status
Sermorelin's regulatory story is unusual among research peptides: it was once an FDA-approved drug for pediatric growth hormone deficiency, but that approved product has since been discontinued in the U.S. market.[3] A discontinued approved drug is not the same as a currently marketed one, and current availability should be verified against FDA and DailyMed records rather than assumed from historical approval.
What is sold today as "sermorelin" is typically a compounded pharmacy product or an unapproved research chemical, neither of which undergoes the FDA's premarket review for safety, effectiveness, or manufacturing quality.[5] Athletes should also note that the World Anti-Doping Agency prohibits growth hormone and growth hormone-releasing factors, which covers sermorelin regardless of whether it is obtained by prescription.[6]